Potentiating the Anticancer Properties of Bisphosphonates by Nanocomplexation with the Cationic Amphipathic Peptide, RALA
Authors:
- 22 March 2016
- journal article
- research article
- Published by American Chemical Society (ACS) in Molecular Pharmaceutics
- Vol. 13 (4) , 1217-1228
Abstract
Bisphosphonates (BPs) are a class of bone resorptive drug with a high affinity for the hydroxyapatite structure of bone matrices that are used for the treatment of osteoporosis. However, clinical application is limited by a common toxicity, BP-related osteonecrosis of the jaw. There is emerging evidence that BPs possess anticancer potential, but exploitation of these antiproliferative properties is limited by their toxicities. We previously reported the utility of a cationic amphipathic fusogenic peptide, RALA, to traffic anionic nucleic acids into various cell types in the form of cationic nanoparticles. We hypothesized that complexation with RALA could similarly be used to conceal a BP’s hydroxyapatite affinity, and to enhance bioavailability, thereby improving anticancer efficacy. Incubation of RALA with alendronate, etidronate, risedronate, or zoledronate provoked spontaneous electrostatic formation of cationic nanoparticles that did not exceed 100 nm in diameter and that were stable over a range of temperatures and for up to 6 h. The nanoparticles demonstrated a pH responsiveness, possibly indicative of a conformational change, that could facilitate release of the BP cargo in the endosomal environment. RALA/BP nanoparticles were more potent anticancer agents than their free BP counterparts in assays investigating the viability of PC3 prostate cancer and MDA-MB-231 breast cancer cells. Moreover, RALA complexation potentiated the tumor growth delay activity of alendronate in a PC3 xenograft model of prostate cancer. Taken together, these findings further validate the use of BPs as repurposed anticancer agents.Keywords
Funding Information
- Engineering and Physical Sciences Research Council (EP/H031065/1)
- Royal Pharmaceutical Society of Great Britain
This publication has 25 references indexed in Scilit:
- Zoledronic acid influences growth, migration and invasive activity of prostate cancer cells in vitroProstate Cancer and Prostatic Diseases, 2012
- Inhibition of breast cancer cell proliferation in repeated and non-repeated treatment with zoledronic acidCancer Cell International, 2012
- Antiangiogenic Effects of Zoledronate on Cancer NeovasculatureFuture Oncology, 2011
- The relationship between the chemistry and biological activity of the bisphosphonatesBone, 2011
- Could targeting bone delay cancer progression? Potential mechanisms of action of bisphosphonatesCritical Reviews in Oncology/Hematology, 2011
- Sustained inhibition of tumor growth and prolonged survival following sequential administration of doxorubicin and zoledronic acid in a breast cancer modelInternational Journal of Cancer, 2009
- The Management of Metastatic Bone Disease with the Combination of Bisphosphonates and Radiotherapy: From Theory to Clinical PracticeAnti-Cancer Agents in Medicinal Chemistry, 2009
- Antitumor Effects of Clinical Dosing Regimens of Bisphosphonates in Experimental Breast Cancer Bone MetastasisJNCI: Journal of the National Cancer Institute, 2007
- Zoledronic Acid Inhibits Visceral Metastases in the 4T1/luc Mouse Breast Cancer ModelClinical Cancer Research, 2004
- Double-blind controlled trial of oral clodronate in patients with bone metastases from breast cancer.Journal of Clinical Oncology, 1993